毛新良

毛新良，博士，教授，博士生導師。為美國血液學學會和美國腫瘤研究協會會員，國家自然科學基金評審專家。毛新良博士在多年的國內外藥物研究中, 積累了豐富的科研經驗, 在分子腫瘤學、腫瘤藥理學、藥物毒理學、基因靶向藥物研究、前體藥物的高效篩選、依據結構活性關係的新藥設計、藥物代謝動力學以及臨床藥理學等方面取得了令人矚目的成就。

基本信息

• 中文名：毛新良
• 民族：漢族
• 國籍：中國
• 畢業院校：同濟醫科大學
• 代表作品：《阿密曲替林的套用》

毛新良，博士，教授，博士生導師。先後畢業於同濟醫科大學（現華中科技大學同濟醫學院）和北京大學。曾獲日本國際交流獎學金赴日本富山醫科藥科大學完成博士論文研究。2000-2004年先後在加拿大麥克馬斯特大學生物化學系和史丹福大學醫學院進行博士後研究。2004年8月-2009年8月多倫多大學安大略省腫瘤研究所從事惡性血液病的靶向新藥研究。2009年9月起受聘蘇州大學唐仲英血液學研究中心，任教授、博士生導師，江蘇省血液學研究所兼職教授。創建了分子靶向白血病新藥研究實驗室（Laboratory for Targeted Anti-Leukemia Drug Discovery）。為美國血液學學會和美國腫瘤研究協會會員，國家自然科學基金評審專家。
毛新良博士在多年的國內外藥物研究中, 積累了豐富的科研經驗, 在分子腫瘤學、腫瘤藥理學、藥物毒理學、基因靶向藥物研究、前體藥物的高效篩選、依據結構活性關係的新藥設計、藥物代謝動力學以及臨床藥理學等方面取得了令人矚目的成就。先後申請了11項美國、國際和中國新藥發明專利，其中1項已經獲得加拿大衛生部批准進行臨床試驗(Phase I/II)。近幾年在Blood、Cancer Research、Oncogene、Journal of Clinical Investigation、European Journal of Pharmaceutics and Biopharmaceutics 等雜誌上已發表近20篇研究論文，均為SCI收錄，平均論文IF>7.0。
主要科研獎項
1. Berlex Research Awards Program, 2006。
2. MCMM Research Fellowship, the McLaughlin Centre for Molecular Medicine, Toronto, 2004
3. MCH Postdoctoral Fellowship, McGill University Children’s Hospital, 2000.
4. AIEJ Scholarship, Association of International Exchange Japan, 1998
目前承擔科研項目
1. 轉錄因子c-maf泛素連線酶cMUL的鑑定及其在多發性骨髓瘤發生髮展和治療中的意義。課題編號：81071935。國家自然科學基金， 負責人, 33萬，2011.01-2013.12。
2. 新型PI3K抑制劑Picromin抗血液腫瘤的機理研究。課題編號：BK2010218.江蘇省自然科學基金，負責人，10萬，2010.07.01-2013.06-30。
3. 抗抑鬱藥阿密曲替林治療多發性骨髓瘤的研製。課題編號：SS201033。蘇州市科技局科技支撐計畫。負責人。15萬。2010.07.01-2013.06.30。
4. 基於納米材料的白血病病因和病理學研究。課題編號：2011CB933501。國家重點基礎研究發展計畫（973計畫）子課題。合作申請人。600萬。2011.01-2015.12。
5. Structural and functional studies of c-Maf sumoylation. departmental Collaborative Research Fund, Chinese University of Hong Kong. Co-PI（20% share）。HK$150,000. 2010.07.01-2011.12.31。
代表性論文
1. MaoXinliang, Cao B, Wood TE, Hurren R, Tong J, Wang X, Wang W, Li J, Jin Y, Sun W, Spagnuolo PA, MacLean N, Moran MF, Datti A, Wrana J, Batey RA,Schimmer AD.A small molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood, revised.
2. Li X, Wood T, Sprangers R, Jansen G, Franke F, Mao Xinliang, Wang X, Zhang Y, Verbrugge SE, Li Z, Trudel S, Chen C, Jamal N, messner H, Cloos J, Rose D, Navon A, Batey RA, Kay LE, Schimmer AD. A non-competitive chemical proteasome inhibitor synergizes with and overcomes resistance to Bortezomib. J Natl Cancer Inst., 2010 Jul 21;102(14):1069-82.
3. Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, Gronda M, Skrtic M, Li X, Hurren R, Mao Xinliang,Venkatesan M, Beheshti Zavareh R, Ketela T, Reed JC, Rose D, Moffat J, Batey RA, Dhe-Paganon S, Schimmer AD. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood.2010 Mar 18;115(11):2251-9.
4. Mao Xinliang, Stewart AK, Hurren R, Gronda M, Lee K, Chow S, Liang S, Trudel S, hedley D, and Schimmer AD. Cyproheptadine displays preclinical activity in myeloma and leukemia.Blood,2008 Aug 1;112(3):760-9.
5. Mao Xinliang, Li X, Sprangers M, Wang X, Vengopal A, Wood T, Zhang Y, Kuntz D, Coe E, Stewart AK, Roase D, Batey RA, Kay LE, and Schimmer AD.Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia. 2009 Mar;23(3):585-90. Epub 2008 Aug 28.
6. Tiedemann RE, Mao Xinliang, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK. Identification of kinetin riboside as a Repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest.,2008 May;118(5):1750-64.
7. Mao Xinliang, Stewart AK, Hurren R, Datti A, Zhu X, Zhu Y, Shi C, Lee K, Tiedemann R, Eberhard Y, Trudel S, Liang S, Corey S, Gillis L, Barber DL, Wrana J, Ezzat S, and SchimmerAD. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood, 2007; 110(12):4047-54.
8. Mao Xinliang,Seidlitz E, truant R, HITT M, and Ghosh HP. Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth.Oncogene,2004; 23(33):5632-42.
9. Mao Xinliang,Seidlitz E, Ghosh K, Murakami Y, and Ghosh HP. The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer.Cancer Res.,2003; 63(22): 7979-7985.
10. Zhu X, Mao Xinliang,Hurren R, Schimmer AD, Ezzat S, Asa SL. Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. J Clin Endocrin & Metab.. 2008 Sep;93(9):3610-7.
11. Mao Xinliang,Schimmer AD. The toxicology of Clioquinol. Toxicol Lett.. 2008 Nov 10;182(1-3):1-6.
12. Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K,Mao Xinliang, Suarez Saiz F, Gronda M, Eberhard Y, MacLean N, Ketela T, Reed JC, Moffat J, Minden MD, Batey RA, Schimmer AD. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56.
13. Tiedemann RE, Schmidt J, Shi CX , Zhu YX , Palmer SE , Mao Xinliang,Schimmer AD, Stewart AK. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity NF-kB with specific anti-myeloma activity in vitro and in vivo. Blood, 2009 Apr 23;113(17):4027-37.
14. Ren X, Mao Xinliang, Cao L, Xue K, Si L, Qiu J, Schimmer AD, Li G. Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. Eur J Pharm Sci. 2009 Mar 2;36(4-5):401-11.
15. Ren X, Mao Xinliang, Si L, Cao L, Xiong H, Qiu J, Schimmer AD, Li G. Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
16. Mao Xinliang, Zhu X, Hurren R, Ezzat S, and Schimmer AD. Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells.Leukemia Res.2008 Sep;32(9):1480-2.
17. Sprangers R, Li X, Mao Xinliang, Rubinstein JL, Schimmer AD, Kay LE. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors.Biochemistry.2008 Jul 1;47(26):6727-34.
18. Wood TE, Dalili S, Simpson CD, Hurren R, Mao Xinliang,Saiz FS, Gronda M, Eberhard Y, Minden MD, Bilan PJ, Klip A, Batey RA, Schimmer AD. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther.2008, Nov; 7(11): 3546-55.
19. Yip KW, Mao Xinliang, Au pyb, Hedley DW, Chow S, Mocanu JD, Bastianutto C, Schimmer AD, Liu FF. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.Clin Cancer Res.2006, 12(18):5557-5569.
20. Yip KW, Ito E, Mao Xinliang, Au PY, Hedley DW, Mocanu JD, Bastianutto C, Schimmer A, Liu FF. Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Mol Cancer Ther.,2006;5(9):2234-40.
申請專利 （共11項）
抗腫瘤新藥相關的美國專利5項，國際專利4項，中國專利2項
1. Inhibiting D-cyclin polypeptide.. US patent Serial No 60/850,567. Filed on Oct. 10, 2006. Inventors: Keith Stewart, Aaron D. Schimmer, and Xinliang Mao
2. Cyproheptadine for the treatment of acute myeloid leukemia and multiple myeloma. US patent Serial No. 60/889,881. Filed on Feb.19th, 2007. Inventors: Aaron D. Schimmer, Xinliang Mao, and Keith Stewart.
3. Clioquinol as an oral copper-dependent inhibitor of the proteosome for the treatment of leukemia and multiple myeloma. Serial No.:US60/980,783. Filed on Oct.18, 2007. Inventors: Aaron D. Schimmer, Xinliang Mao, and Keith Stewart.
4. Pichromene for the treatment of hematological malignancies. Serial No.: US61/110,064. Filed on Oct 31, 2008. Inventors: Aaron Schimmer, XinliangMao
5. Compounds for the treatment of hematological malignancies. Serial No.: US61/112,911. Filed on Nov 10, 2008. Inventors: Aaron Schimmer, Xiaoming Li, Robert Batey, Tabitha Wood ,Xinliang Mao
6. Inhibiting D-cyclin polypeptide, PCT Application No.: PCT/US2007/080978. Filed on 2007-10-10. Inventors: Keith Stewart, Aaron D. Schimmer, and Xinliang Mao
7. Treatment of D-cyclin mediated proliferative diseases and Hematological malignancies, PCT Application No.: WO2008098351. Filed on 2008-02-12. Inventors: Aaron D. Schimmer, Xinliang Mao, and Keith Stewart.
8. Clioquinol for the treatment of hematological malignancies. PCT Application No.: PCT/CA2008/001812. Filed on 2008-10-16. Inventors: Aaron D. Schimmer, Xinliang Mao, and Keith Stewart.（已在加拿大進入臨床試驗I/II期）
9. 8-Hydroxyquinoline derivatives for the treatment of hematological malignancies. PCT Application No.: PCT/CA2009/000776. Filed on 2009-05-06.. Inventors: Aaron D. Schimmer, Xiaoming Li, Robert Batey，TabithaWood，Xinliang Mao.
10. 阿密曲替林的套用。中國國家知識產權局，專利申請號：201010125834.7. 申請日期：2010年3月9日。發明人：毛新良。
11. 一種磷脂醯肌醇-3-激酶抑制劑及其套用。中國國家知識產權局，專利申請號：201010181572.6. 申請日期：2010年5月25日。 發明人：毛新良；艾倫·什莫。
研究方向：
1) 基因靶向小分子抗癌藥物的高效篩選研究
2) 腫瘤分子藥理學
3) 腫瘤分子生物學
4) 藥物毒理學
5) 臨床藥理學